129
Views
0
CrossRef citations to date
0
Altmetric
Original Research

A Comparative Evaluation of an Automated Functional Assay for Von Willebrand Factor Activity in Type 1 Von Willebrand Disease

, , , , &
Pages 5167-5174 | Published online: 02 Sep 2021

References

  • Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–459.
  • Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893–898.
  • Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–216.
  • Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160–174.
  • Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost. 2005;31(5):569–576.
  • Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262(18):8443–8446.
  • Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000;105(6):783–791.
  • Doggett TA, Girdhar G, Lawshe A, et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond. Biophys J. 2002;83(1):194–205.
  • Leebeek FW, Eikenboom JC. Von Willebrand’s Disease. N Engl J Med. 2016;375(21):2067–2080.
  • Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–2065.
  • Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831–835.
  • James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300.
  • Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114.
  • Robertson J, Lillicrap D, James PD. Von Willebrand disease. Pediatr Clin North Am. 2008;55(2):377–392, viii–ix.
  • Flood VH, Christopherson PA, Gill JC, et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016;127(20):2481–2488.
  • Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: a method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh. 1975;34(1):306–308.
  • Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia. 2008;14(2):171–232.
  • Mori F, Rossi P, Nardini I, Gambelli D, Farina C. Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test. Blood Coagul Fibrinolysis. 2010;21(3):221–228.
  • Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis. 2004;15(6):505–511.
  • Redaelli R, Corno AR, Borroni L, et al. von Willebrand factor ristocetin cofactor (VWF:RCo) assay: implementation on an automated coagulometer (ACL). J Thromb Haemost. 2005;3(12):2684–2688.
  • Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost. 2006;12(1):61–67.
  • Salem RO, Van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol. 2007;127(5):730–735.
  • Pinol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB. Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica. 2007;92(5):712–713.
  • Chen YC, Yang L, Cheng SN, Hu SH, Chao TY. von Willebrand disease: a clinical and laboratory study of sixty-five patients. Ann Hematol. 2011;90(10):1183–1190.
  • Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–1695.
  • Olson JD, Brockway WJ, Fass DN, Magnuson MA, Bowie EJ. Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation. Am J Clin Pathol. 1975;63(2):210–218.
  • Federici AB, Castaman G, Mannucci PM. Italian association of Hemophilia C. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002;8(5):607–621.
  • Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004;10(Suppl 4):169–176.
  • Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006;32(5):492–498.
  • Preston FE. Laboratory diagnosis of hereditary bleeding disorders: external quality assessment. Haemophilia. 1998;4(Suppl 2):12–18.
  • Patzke J, Schneppenheim R. Laboratory diagnosis of von Willebrand disease. Hamostaseologie. 2010;30(4):203–206.
  • Milos M, Herak D, Kuric L, Horvat I, Zadro R. Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer - HemosIL reagents. Int J Lab Hematol. 2009;31(1):26–35.
  • Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program. 2009;106–112. doi:10.1182/asheducation-2009.1.106
  • Sadler JE. A revised classification of von Willebrand disease. For the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71(4):520–525.
  • Appert-Flory A, Fischer F, Jambou D, Toulon P. Evaluation and performance characteristics of the automated coagulation analyzer ACL TOP. Thromb Res. 2007;120(5):733–743.
  • Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia. 2011;17(2):252–256.
  • Vinayagam S, Simons LR, Chowdary P, Thurlow P, Brooks SV, Riddell AF. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy. Haemophilia. 2014;20(4):e304–310.
  • Chen D, Daigh CA, Hendricksen JI, et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost. 2008;6(2):323–330.
  • De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis. 2006;17(5):353–358.
  • Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost. 2010;8(10):2216–2223.